M&A - Dianthus Therapeutics, Inc. /DE/

Form Type: 10-K

Filing Date: 2025-03-11

Corporate Action: Merger

Type: Update

Accession Number: 000095017025037131

Filing Summary: Dianthus Therapeutics, Inc., after completing a merger on September 11, 2023, with Former Dianthus, has transitioned its structure and operations. This document outlines the financial condition, operational strategies, and future plans for the clinical-stage biotechnology company, which focuses on developing complement therapeutics targeting autoimmune and inflammatory diseases. Its lead product candidate, DNTH103, is in mid to late-stage trials for conditions such as generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company has also evaluated its capital resources and reported an aggregate market value of $651 million for its common equity as of June 30, 2024, with approximately 32.1 million shares outstanding as of March 7, 2025. Other key areas discussed include risk factors, internal controls, financial statements, and future operational forecasts. The report emphasizes ongoing investments in research and development, highlighting the challenges and opportunities facing the company as it continues its clinical programs and aims for future FDA approvals.

Document Link: View Document